PJ Psych: Assisted suicide is being fast-tracked: what about those of us living with despair?

The British Journal of Psychiatry


Article contents

Assisted suicide is being fast-tracked: what about those of us living with despair?

Published online by Cambridge University Press:  09 February 2026

James Downs[Opens in a new window]

Show author details


Save PDFShareCite

Rights & Permissions[Opens in a new window]


Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.


Keywords

Suicidestigma and discriminationassisted dyingpsychiatry and lawhuman rights


Information

TypeLetterInformation

The British Journal of Psychiatry First View , pp. 1 – 2

DOI: https://doi.org/10.1192/bjp.2026.10535[Opens in a new window]

Copyright

© The Author(s), 2026. Published by Cambridge University Press on behalf of Royal College of Psychiatrists


In writing this letter, I do not intend to debate assisted suicide itself. Rather, as someone who lives with chronic suicidality due to mental illness, I have found the recent discourse around ending one’s life complicated and painful. Although there are fundamental differences between living with chronic suicidality and the process of dying, Reference Friesen1 the policies being considered by legislators bring into focus the persisting disparities in how society understands and responds to mental illness as compared with physical illness.

The UK Parliament’s proposed legislation for assisted suicide, as a legal and clinical service, is framed as a compassionate response to those experiencing refractory end-of-life suffering. Reference Burki2

As the UK moves towards implementing assisted suicide for people with terminal illnesses, the public debate has been shaped by advocates who emphasise dignity, personal autonomy and compassion. Reference Harwood3 These are values we all want to see upheld in healthcare: compassion is a foundational ethical principle across health professions, embedded in medical guidelines internationally. Reference Behan and Kelly4

What does it mean when the desire to die is met with compassion and understanding in one context, but feared, dismissed or punished in another?

Living with chronic suicidality

I have lived with suicidal thoughts stemming from complex mental illness for the most part of two decades. There are times when I want to die more than anything else. There are also times when I desperately want to live but can’t feel any hope. In between, there are long periods where I survive more than I live and have very few days without some kind of ambivalence between wanting (and not wanting) to live (or to die).

Awareness campaigns encourage us to ‘reach out’, Reference Henderson, Robinson, Evans-Lacko and Thornicroft5 but I’ve only ever been able to access clinical care after a crisis. Even then, I have often felt blamed for my symptoms by professionals who have labelled them as ‘attention seeking’ or used the abstract word ‘behavioural’ to explain them. Conversations about suicidality, on the few occasions when they have taken place, have rarely been compassionate.

The right kind of suicidal

The debate around assisted suicide both highlights and reinforces a persisting divide in how society regards physical suffering versus mental suffering. Reference Behan and Kelly4 The person whose body is failing owing to terminal illness has their pain acknowledged as legitimate. They are not seen as irrational; their death is part of the natural order, and their decision is met with empathy. New services for them have been modelled at pace in Parliament, with the promise of all the funding they need.

This lies in stark contrast to the lack of progress in providing understanding and support for those who feel suicidal as a result of mental illness. Many of us wait years for any meaningful response at all. The services we need are under-resourced, or do not exist. The message this sends is clear: there is a ‘right’ kind of suicidal, and ours is not it.

This hierarchy has significant clinical consequences. When mental illness is seen as a form of suffering that is less worthy of attention and support, this reinforces stigma and hopelessness, creating a damaging cycle in which people are discouraged from seeking help or seeing their struggles as valid.

Compassion as a safeguard

Assisted suicide is framed as a compassionate act, preventing the distress of a painful death. But compassion is not always about alleviating suffering, nor it merely a sentiment. Compassion is something that is enacted – through empathy, presence and kindness. Reference Gilbert6 These practices depend on the structures of healthcare, including sufficient training and resources that equip clinicians with the skills and space to offer compassion ate responses sustainably. Reference Harwood3,Reference Baguley, Pavlova and Consedine7

In my own experience, I am grateful for the times when clinicians enacted compassion in ways that were not necessarily ‘soft’ – for being fiercely protective of my life when I have wanted to discard it. I am here today because of professionals who have held a firm line with me, even when I have pushed them away, and have understood that the kind thing to do doesn’t always feel kind for the patient, or for themselves.

If we’re going to talk about assisted dying with the language of compassion, then we need to talk about compassionate responses to mental illness with the same depth and nuance. Reference Malhi8 For someone like me, who isn’t dying but often wants to, I need the law to protect me: from under-resourced systems, from clinicians afraid to talk about suicide and from myself on the days when I am convinced that dying is the answer. That, to me, is compassion.

The same nuance is needed when considering patients’ rights to make decisions. Achieving parity of esteem between mental and physical illness is not about offering the same outcome. Although patients have rights, that doesn’t mean that our views are always right, especially when we are in the grip of suicidality. This is when our right to life must take priority, even if it is not our own priority at the time.

Making space for suicidality

Too often, clinicians have either treated my suicidality as a pathology to be controlled and a risk to be managed, or ignored, trivialised and dismissed it as something I’m not really that serious about. In both cases, the reality of my suffering has been sidestepped, either by being erased or denied. Between these two forms of avoidance has been my unmet need for attention, presence and listening. What I have needed most has been someone to sit with me in my suffering and to listen without trying to change, minimise or deny my experience.

Being alongside those who are suicidal is not about agreeing with their thoughts or actions; it is about embedding listening and presence as central components of compassionate care, especially in the context of systems where these practices can easily be overshadowed by excess pressures and efficiency demands. Reference Gilbert6 Public discourse and clinical practice alike need to make recognise that the suffering of mental illness deserves to be met with just as much resource, respect and compassion as terminal illness.

If dying well matters, so should living

I want people who are dying to have as much support as possible to die well. But I also want people who are suicidal to have the chance to live well. Part of this is being able to speak about wanting to die without being met with fear or avoidance. It also requires clinical environments in which staff have the time, training and support to respond with empathy and presence, so that compassion becomes a lived reality rather than an aspiration.

If our politicians can fast-track services to assist those with terminal illnesses to die, they must also act to improve the healthcare that is offered to those who are choosing, every day, to stay alive.

Funding

This letter received no specific grant from any funding agency, commercial or not-for-profit sectors.

Declaration of interest

None.


References

1

Friesen, P. Medically assisted dying and suicide: how are they different, and how are they similar? Hastings Cent Rep 2020; 50: 32–43.10.1002/hast.1083CrossRefGoogle ScholarPubMed

2

Burki, T. UK House of Commons passes assisted dying bill. Lancet Oncol 2025; 26: 997.10.1016/S1470-2045(25)00405-XCrossRefGoogle Scholar

3

Harwood, RH. We should not fear assisted dying. Age Ageing 2025; 54: afaf029.10.1093/ageing/afaf029CrossRefGoogle Scholar

4

Behan, C, Kelly, B Handbook of Compassion in Healthcare: A Practical Approach. Cambridge University Press, 2025.10.1017/9781009390217CrossRefGoogle Scholar

5

Henderson, C, Robinson, E, Evans-Lacko, S, Thornicroft, G. Relationships between anti-stigma programme awareness, disclosure comfort and intended help-seeking regarding a mental health problem. Br J Psychiatry 2017; 211: 316–22.10.1192/bjp.bp.116.195867CrossRefGoogle ScholarPubMed

6

Gilbert, P. Compassion: from its evolution to a psychotherapy. Front Psychol 2020; 11: 586161.10.3389/fpsyg.2020.586161CrossRefGoogle ScholarPubMed

7

Baguley, SI, Pavlova, A, Consedine, NS. More than a feeling? What does compassion in healthcare ‘look like’ to patients? Health Expect 2022; 25: 1691–702.10.1111/hex.13512CrossRefGoogle ScholarPubMed

8

Malhi, GS. Assisted dying for mental illness: a contemporary concern that requires careful and compassionate consideration. Br J Psychiatry 2024; 225: 259–61.10.1192/bjp.2024.116CrossRefGoogle ScholarPubMed

Posted in Uncategorized | Tagged , , , , | Leave a comment

El Pais: ADHD overdiagnosis is harming gifted children

ADHD overdiagnosis is harming gifted children

Their behaviors are similar, but their needs are different

Juárez Casanova

Olga Carmona

FEB 12, 2026 – 12:00 CET

Share on Whatsapp

Share on Facebook

Share on Twitter

Share on Bluesky

Share on Linkedin

Copy link

In recent years, diagnoses of attention deficit hyperactivity disorder (ADHD) have multiplied. More and more children are being labeled as inattentive or impulsive, and many are receiving medication, which can be as unnecessary as it is harmful. This is not only due to the potential and as-yet-undocumented long-term consequences of altering a still-developing brain that doesn’t require it with psychotropic drugs, but also because of the implicit message it conveys: “You’re not okay, you have to take pills.” This isn’t about being against medication, but about being against misdiagnosis.

In recent studies and in our daily clinical practice, we see a clear overdiagnosis of ADHD and its confusion with giftedness. In many cases, what is seen as distractibility or lack of control is actually a mismatch between the child’s pace and that of the educational environment.

Much of this stems from teachers’ limited training on how the brain works and how gifted students learn. Teachers are the first observers, but without specific training, they tend to pathologize behavior. A bored student may come across as inattentive, and one who asks questions, as disobedient. As psychologists Juan E. Jiménez and Ceferino Artiles point out, a lack of understanding of advanced cognitive development leads to labeling adaptive behaviors indicative of talent as pathological symptoms.

Gifted children process information very quickly and their attention is selective. They concentrate deeply when something interests them, but tune out when faced with monotony, repetition, or slowness. Unlike ADHD, their attention is not impaired, but rather influenced by motivation, challenge, and the complexity of the task. Their divergent thinking may manifest as off-topic questions or creative interruptions, easily mistaken for impulsivity.

In 2020, the Ayalga Center, specializing in psychology and education, published a study on brain function in gifted children through the systematic observation of executive functions. These studies conclude that gifted children have difficulties with specific tasks: they are restless children who frequently act impulsively, tend to lose control more than others, get up from their chairs when they shouldn’t, speak out of turn, and struggle to recognize that certain actions bother others or to distinguish between their strengths and weaknesses.

In terms of flexibility and emotional control, we’re talking about children who frequently feel uncomfortable in new situations, dwell on the same issue repeatedly, struggle to accept alternative solutions to problems, experience frequent mood swings, and overreact to minor details. Regarding initiative, they find it difficult to start activities on their own, even when they are willing.

These children have difficulty remembering information: for example, if you give them three things to do, they only remember the first or the last. Related to this is their planning and organization skills: they struggle to estimate the time they need to complete a task, have difficulty putting their ideas into writing, or become overwhelmed by lengthy assignments. These tasks can result in sloppy execution: poor handwriting, lack of proofreading, and careless mistakes. They frequently forget to bring home school assignments, hand in homework—even if they have completed it—or even find their own belongings. They are driven by curiosity and a desire for meaning. When learning lacks challenge, frustration and boredom arise, easily mistaken for inattention. Furthermore, they often exhibit emotional hypersensitivity and react intensely to inconsistency or injustice, which may appear impulsive but reflects great emotional depth.

Overdiagnosis of ADHD in gifted students leads to unnecessary medication and clinical labeling, obscuring the child’s potential. The opportunity to adapt the educational environment to their pace is lost, and demotivation is fostered. Many gifted adolescents show up at our office feeling that they are the problem.

The goal is not to reject diagnoses, but to refine our perspective. The evaluation should analyze situational attention, motivation, cognitive profile, and learning style. It is essential to observe whether inattention is generalized or context-dependent, and whether restlessness stems from curiosity or difficulty with self-control. A rigorous diagnosis requires distinguishing between structural deficits and situational or motivational differences.

The challenge is not to diagnose more or less, but to diagnose better. Mistaking high intellectual ability for a disorder causes emotional wounds. When a highly gifted child is treated as a problem, the implicit message is devastating: “It’s not okay to be the way you are.” Understanding high abilities involves changing our perspective: from deficit to difference, from pathology to potential.

Sign up for our weekly newsletter to get more English-language news coverage from EL PAÍS USA Edition

Posted in Uncategorized | Tagged , , , , | Leave a comment

Axios: Musk celebrates Medicaid win (Remember DOGE)

Musk celebrates Medicaid win
 
Photo illustration of Elon Musk against an abstract background.
Photo illustration: Shoshana Gordon/Axios. Photo: Al Drago/Bloomberg via Getty Images
 
Elon Musk took a victory lap yesterday as a DOGE team released a huge trove of Medicaid spending data he said the public could use to look for fraud themselves, Axios’s Adriel Bettelheim and Maya Goldman write.

Why it matters: The Trump administration often cites waste as justification for deep program cuts including the nearly $1 trillion in reductions to federal Medicaid spending in last year’s Republican budget bill.

Between the lines: The public release could make it possible to identify high-billing Medicaid providers and unusual patterns — including alleged fraudulent autism diagnoses and treatments in Minnesota that were billed by Medicaid providers, The Wall Street Journal wrote in an editorial (gift link).

The administration used Minnesota’s inability to rein in fraud in safety net programs as justification for freezing federal child care funding and launching the ICE enforcement surge that targeted the state’s Somali community.Share this story.

Posted in Uncategorized | Leave a comment

Axios: Claude’s Venequela drama

Claude’s Venezuela drama
 
Man in cuffs
Nicolás Maduro arrives at a Manhattan helipad after his capture. Photo: XNY/Star Max/GC Images
 
The U.S. military used Anthropic’s Claude AI model during the operation to capture Venezuela’s Nicolás Maduro. Now the blowback may threaten the company’s business with the Pentagon, sources with knowledge of the situation told Axios’s Dave Lawler and Maria Curi.

Why it matters: Defense Secretary Pete Hegseth has leaned into AI and said he wants to quickly integrate it into all aspects of the military’s work, in part to stay ahead of China.

The big picture: The Pentagon wants the AI giants to allow them to use their models in any scenario, so long as they comply with the law.

Anthropic, which has positioned itself as the safety-first AI leader, is currently negotiating with the Pentagon around its terms of use. The company wants to ensure its technology is not used for the mass surveillance of Americans or to operate fully autonomous weapons.

Our sources said Claude was used during the Maduro active operation, not just in preparations for it, though its precise role remains unclear.

The company is confident the military has complied in all cases with its existing usage policy, which has additional restrictions, a source familiar with the ongoing discussions told Axios.🚨 

A senior administration official told Axios last night that Anthropic questions about Claude’s use in the operation raised Pentagon concerns.

Any company that would jeopardize the operational success of our warfighters in the field is one we need to reevaluate our partnership with going forward,” the official said.

An Anthropic spokesperson denied that the company made “any such call to the Department of War.”The spokesperson told Axios: We cannot comment on whether Claude, or any other AI model, was used for any specific operation, classified or otherwise.”

Zoom out: Anthropic is one of several major model-makers that are working with the Pentagon

OpenAI, Google and xAI have reached deals for military users to access their models without many of the safeguards that apply to ordinary users.

Anthropic also has a partnership with Palantir, the AI firm with extensive Pentagon contracts, that allows it to use Claude within its security products. Share this story.

Posted in Uncategorized | Tagged , , , , | Leave a comment

Piers Morgan, Uncensored. “A VERY Valuable Asset” Epteins Links to Mossad

Posted in Uncategorized | Leave a comment

GZERO: How the US went from global cop to King of the Jungle. Ian Bremmer

Posted in Uncategorized | Leave a comment

SCIAM: Why did Jeffrey Epstein cultivate famous scientists?

Why did Jeffrey Epstein cultivate famous scientists?

The Epstein files revive questions of whether the disgraced financier sought to merely cultivate famous scientists, or to shape science itself

By Dan Vergano edited by Clara Moskowitz

A group of men and women seated and standing for a group photograph in front of a round pink table.
Jeffrey Epstein with professors at a dinner he hosted at Harvard University in September 2004. Rick Friedman/Alamy

Ethics

Last December, the U.S. Department of Justice released its first batch of files on disgraced financier and convicted sex offender Jeffrey Epstein. Among the thousands of images was one video clip, the only one in the lot. It showed four seconds of the noted psychologist and writer Steven Pinker of Harvard University riding with Epstein on his now infamous private plane.

It wasn’t a great flight even in 2002, years before Epstein’s first criminal conviction, Pinker says of the trip, which was heading to a TED Talk. “I immediately disliked Epstein and thought he was a dilettante and a smartass,” he says. Pinker has not been accused of wrongdoing in connection with Epstein.

Epstein, who died in federal prison in 2019 while awaiting trial on sex trafficking charges, spent a lot of time talking to scientists. When more records are released from a reported stash of 5.2 million, now a month overdue, questions about what the “Epstein files” say about science and scientists are sure to arise. Already, e-mails dropped by a congressional committee and files released by the DOJ—thousands of notes, lists, videos and investigation records—have once again raised the question of why so many prominent scholars were involved with Epstein.

The financier widely courted punditspoliticians and billionaires, as the DOJ files confirm with photographs of everyone from Mick Jagger to Bill Clinton to Donald Trump appearing with him. (None are charged with wrongdoing in connection to the photographs.) A piano virtuosomysteriously wealthy and famously ingratiating, Epstein courted scientists for years, leading to investigations at the Massachusetts Institute of Technology and Harvard, the results of which were made public in 2020. Last year’s e-mail releases revealed that astronomer Lawrence Krauss and linguist Noam Chomsky both associated with him long after his crimes became public knowledge. Last November Harvard launched a new investigation to look at connections between Epstein and economist Lawrence Summers, former president of the university.

Patronage

Money is one easy answer for why scientists were interested in Epstein. “Scientists need patronage; they need support,” says Bruce Lewenstein, a science communications expert at Cornell University. Wealthy patrons have funded scientists for centuries; they have paid for telescopes to investigate the atmospheres of alien worldsbrain mapping institutesmalaria prevention experiments, and much else. “That’s not good or bad; that’s what it is. And that has been true for 400 years,” Lewenstein says. Unlike many donors, Epstein usually wasn’t asking for his name on a building, and he donated money to everything from dance troupes to the Council on Foreign Relations, according to a 2019 Miami Herald report.

Curated by Our Editors

Before his 2008 conviction for soliciting minors for prostitution, Epstein donated more than $9 million to Harvard, including a $6.5-million gift to Harvard’s Program for Evolutionary Dynamics (PED), led by mathematician Martin Nowak. (Epstein continued to visit that program after his conviction—he did so more than 40 times in 2018 alone—and kept an office there.) He was also a Visiting Fellow at the university in the 2005–2006 academic year, after making a $200,000 gift to its psychology department. Following his conviction, donors he introduced to Harvard scientists gave $9.5 million to the school.

Then there were Epstein’s donations to M.I.T.: he donated $525,000 to the MIT Media Lab and $225,000 to mechanical engineering professor Seth Lloyd. Both gifts came after his 2008 conviction and were handled outside normal channels, according to a university report. Epstein claimed to also have arranged another $7 million in donations from billionaires Bill Gates and Leon Black to the school (Gates denied this, and the university report says there’s no evidence of an effort to “launder” Epstein’s money in the donations).

“The only generalization is that scientists, like the universities they work for, together with artists and others in nonprofit ventures that depend on philanthropy, routinely cozy up to wealthy people willing to slosh money around,” Pinker says. “Very few of these donors are heinous psychopaths, and he exploited their gullibility.”

According to Pinker, his pre-TED Talk flight with Epstein came at the behest of his literary agent, John Brockman, whose Edge Foundation also threw salons for Epstein that BuzzFeed News described as an “exclusive intellectual boys club.” (Brockman and his organization did not respond to a request for comment, and no reports of wrongdoing attended the events.) Epstein funded that foundation, which threw parties for billionaires and made contacts with people such as Pinker for him. Those contacts paid off: despite his dislike for Epstein, Pinker unwittingly contributed to the financier’s legal defense. Pinker wrote a 2007 opinion on the semantics of the wording of a prostitution law as a favor for Harvard professor Alan Dershowitz, who was Epstein’s lawyer and had once taught a course with Pinker. Pinker has said he didn’t know the opinion was for Epstein’s defense.

“I was doing a professional courtesy to a colleague—it’s routine,” Pinker says. “If I knew at the time what we know now, I would not have agreed.”

A man standing in front of a chalkboard that is covered in equations.
Epstein in a Harvard classroom in September 2004.Rick Friedman/Alamy

Celebrity

So, legal opinions aside, what did Epstein want from science? The simplest explanation is that Epstein collected prominent people. His financial networking relied on creating an aura of wealth and influence to entice investors. He was a “people collector” who traded information and favors, said Barry Levine, one of his biographers, in a 2025 BBC report. Scientists might have just been one of many influential groups he cultivated at a time that was “a cultural high-water mark for scientists as celebrities,” says Declan Fahy, an associate professor of science communication at Dublin City University in Ireland and author of The New Celebrity Scientists. Scientists wrote best-selling books, appeared in Vanity Fair and Vogue and gave viral TED Talks that were elevated online. “They moved into the power elite,” Fahy says, and so made sense for Epstein to cultivate.

Sign Up for Our Daily Newsletter

I agree my information will be processed in accordance with the Scientific American and Springer Nature Limited Privacy Policy. We leverage third party services to both verify and deliver email. By providing your email address, you also consent to having the email address shared with third parties for those purposes.Sign Up

According to Ghislaine Maxwell, Epstein’s former girlfriend and majordomo, who was convicted in 2021 of sex trafficking, conspiracy and transportation of a minor for illegal sexual activity, Epstein was particularly fascinated by brain science. In a July 2025 interview Maxwell told the DOJ that connections she had made through her father, Robert Maxwell, founder of scientific publisher Pergamon Press, led to her introducing Epstein to the Santa Fe Institute, a home to many high-profile scientists. (Epstein donated $25,000 to the institute in 2010.) “Epstein would have dinners at the house that I was tasked to organize and the scientists were a very major component of that,” she said, according to the DOJ transcript.

The scientist and writer Evgeny Morozov attributed Epstein’s scientific connections to Brockman—the literary agent who, according to Pinker, talked the psychologist onto Epstein’s plane—in a 2019 article in the New Republic. Himself a former Brockman client, Morozov recounted the agent’s attempts to connect him to Epstein and his “billionaires’ dinners,” whose attendees often were TED Talk speakers—invitations that Morozov declined.

The Edge Foundation was ubiquitous in science writing circles from 1998 to 2018, annually publishing books on scientific topics. It was also connected to the physicist Lawrence Krauss, a former member of Scientific American’s board of advisers, who was removed following sexual misconduct allegations in 2018. Released e-mail records show that Krauss asked Epstein for advice on handling those charges. Krauss has denied the misconduct allegations against him; none of the communications cited allege wrongdoing in connection with Epstein. (In 2014 Epstein was even invited to two Scientific American editorial meetings, which he did not attend.) Public records suggest the Edge Foundation received $638,000 from Epstein from 2001 to 2015, making him its major funder.

Social Prosthetics

One disturbing explanation for Epstein’s support of science comes from his interest in genetic determinism. This idea, which dates to the eugenics era, is still fashionable in some wealthy circles and can be seen in companies now offering designer baby services for embryos of would-be parents. In 2019 the New York Times reported that Epstein had ambitions of founding a “baby ranch” to raise children of women he impregnated (not unlike “secret compound” plans reportedly shared by SpaceX and Tesla chief Elon Musk).

“Given this stance, it is particularly disturbing that he focused his largesse on research on the genetic basis of human behavior,” wrote Naomi Oreskes, a historian of science, in Scientific American in 2020. “Scientists might claim that Epstein’s money in no way caused them to lower their standards, but we have broad evidence that the interests of funders often influence the work done.” (Regarding Epstein, Oreskes now adds, “The continued press attention reminds us that—rightly or wrongly—we are judged by the company we keep, and some money is tainted.”)

Perhaps the only direct evidence of Epstein’s scientific ambitions comes from a proposal he made in 2005 to be a Visiting Fellow at Harvard. “I wish to study the reasons behind group behavior, such as ‘social prosthetic systems,’” he wrote in an application proposing magnetic resonance imaging studies on human volunteers. “That is, other people can act as ‘prosthetics’ insofar as they augment our cognitive abilities and help us to regulate our emotions—and thereby essentially serve as extensions of ourselves,” he added, with a scientific gloss neatly encapsulating his view of humanity’s role in his life. Harvard approved him twice for the fellowship, though a 2020 investigation later noted his utter lack of qualifications.

A Rocky Pedestal

One last question is why anyone is surprised that celebrity scientists fell into Epstein’s orbit—as opposed to, say, rock stars or politicians doing so—in a culture driven by the worship of wealth and celebrity.

“A bit of this is [because] we have created an idealized picture of scientists that doesn’t match reality,” Lewenstein says. Scientists themselves like being seen as experts with their status on a pedestal, he adds. “They are very reluctant to acknowledge the social forces that shape their science,” Lewenstein says.

In other words, money talks in science. For decades, pharmaceutical-industry-funded research, for example, has more often reported favorable results in medicine. And money can control what science projects don’t get done; social media companies such as Facebook and X (formerly Twitter) have shut out researchers from examining their data—a vast, barely regulated experiment on billions of people linked to worse mental health in children. At the National Institutes of Health right now, in a very different era for science than one of celebrity, Trump administration political appointees are approving or disapproving allocations of the agency’s $48-billion budget for investigations judged as worthy by actual scientists, overturning the post–World War II standards for funding research.

Most of the scientists supported by Epstein weren’t overtly political and supported a once-uncontroversial view of science as an engine of progress, Fahy says. Things are different now, “where public debate around science in the U.S.—particularly around climate and vaccination—has become sharper, divisive, intensely political,” he adds.

All that leaves Pinker unsure why his four seconds on the plane in 2002 was the only video in the Epstein files to be initially released by the Trump administration. One reason might be to generate news stories such as this one about scientists, he says. “The more that journalists write about other people in photos, the less attention Trump’s entanglement gets,” Pinker says.

Rights & Permissions

Dan Vergano is senior editor, Washington, D.C., at Scientific American. He has previously written for Grid News, BuzzFeed News, National Geographic and USA Today. He ischair of the New Horizons committee for the Council for the Advancement of Science Writing and a journalism award judge for both the American Association for the Advancement of Science and the U.S. National Academies of Sciences, Engineering, and Medicine.

More by Dan Vergano

It’s Time to Stand Up for Science

If you enjoyed this article, I’d like to ask for your support. Scientific American has served as an advocate for science and industry for 180 years, and right now may be the most critical moment in that two-century history.

I’ve been a Scientific American subscriber since I was 12 years old, and it helped shape the way I look at the world. SciAm always educates and delights me, and inspires a sense of awe for our vast, beautiful universe. I hope it does that for you, too.

If you subscribe to Scientific American, you help ensure that our coverage is centered on meaningful research and discovery; that we have the resources to report on the decisions that threaten labs across the U.S.; and that we support both budding and working scientists at a time when the value of science itself too often goes unrecognized.

In return, you get essential news, captivating podcasts, brilliant infographics, can’t-miss newsletters, must-watch videos, challenging games, and the science world’s best writing and reporting. You can even gift someone a subscription.

There has never been a more important time for us to stand up and show why science matters. I hope you’ll support us in that mission.

Thank you,

David M. Ewalt, Editor in Chief, Scientific American

Subscribe

Posted in Uncategorized | Tagged , , , , | Leave a comment

Qualified Health and the University of Texas System use Claude to identify patients who need life-saving care

Get started

Get started

Industry:

Healthcare

Company size:

Large

Product:

AI Platform

Location:

North America

4–6 million patients per year

in Texas qualify for evidence-based interventions but never get identified

1 million+ patient population

at The University of Texas Medical Branch now being screened by protocols built on Claude to identify candidates for intervention

Qualified Health is a healthcare-native AI platform that identifies patients who qualify for life-saving treatments and improved evidence-based management but who would otherwise go undetected. The University of Texas System is one of the largest public university systems in the United States, with health institutions serving patients across Texas.

With Claude, Qualified Health and the UT System:

  • Screen a 2 million patient population to identify candidates for life-saving interventions
  • Route eligible patients directly into clinicians’ workflows with supporting documentation
  • Complete chart reviews in minutes that previously required extensive manual abstraction
  • Identify patients who benefit from medication optimization, therapeutic intervention, or further discussion
  • Plan to expand from cardiology to primary care, vascular, GI, rheumatology, and neurology by end of 2026

The problem

In Texas, almost every county experiences some critical physician shortage. Healthcare providers know that catching diseases earlier leads to better outcomes, but the information needed to identify at-risk patients is buried in fragmented clinical data that no human could reasonably review at scale.

“People both want and deserve a level of access to healthcare that our workforce can’t realistically deliver without AI augmentation,” said Dr. Peter McCaffrey, Chief Digital and AI Officer at the University of Texas Medical Branch (UTMB).

Healthcare systems spent years digitizing their records, but digitization didn’t make the data usable. “The problem we face is literally one of search, retrieval, and comprehension,” McCaffrey said. “It’s 90% of what we do. It’s where so much of our workforce gets burned out and it’s where most care gaps accumulate. The size and scope of that data are only growing, the breadth of our responsibility to patients is only growing, but our workforce is not keeping pace.”

Organizations ended up with vast amounts of unstructured clinical notes, imaging reports, and test results scattered across disconnected systems. A patient may receive a new diagnosis of heart failure and may be started on therapy, but those medications and dosages may not align with the latest guidelines. Meanwhile, a Cardiology team–even at the same hospital–may be aware of the latest guidelines, but they would not be aware of whether newly diagnosed patients are receiving guideline-directed care even though doing so improves mortality. In Texas, an estimated 4–6 million patients qualify for evidence-based interventions each year and never get identified—resulting in preventable deaths, avoidable complications, and growing strain on the healthcare system.

Claude powers population-scale patient identification

Qualified Health built an AI platform with Claude Sonnet 4.5 to help health systems identify patients who qualify for proven, evidence-based interventions at population scale. Claude was selected following a structured evaluation of multiple models, based on its performance in accurately extracting clinical information, minimizing hallucinations, and producing outputs that are fully traceable to source data, capabilities required for safe use in clinical settings.

The platform integrates fragmented clinical data, such as notes, laboratory results, imaging, and procedural records, and applies precise, guideline-based clinical criteria to determine patient eligibility across a broad set of cardiology practices. 

Patients who meet those criteria are surfaced directly into clinicians’ existing workflows for review, with supporting documentation generated to trace each finding back to source data. This approach shortens the path from identification to treatment while preserving clinician oversight, enabling health systems to deliver evidence-based care more consistently and at a scale that was previously infeasible.

From reactive care to proactive intervention

Justin Norden, MD, a physician and computer scientist, founded Qualified Health to help health systems deploy AI safely and at scale across clinical and administrative operations, enabling clinicians to find and treat patients who would otherwise fall through the cracks. His previous company focused on algorithm safety and trust in high-risk environments before being acquired for autonomous vehicle applications. That background shaped Qualified Health’s approach: building the infrastructure needed to monitor, validate, and govern AI performance in high-risk healthcare settings.

“If we caught patients earlier and intervened, that would be better for everyone. That’s very well known,” said Norden. “What is not yet well known is that today, we have the potential to do that.”

The partnership with the UT System began when Dr. McCaffrey was expanding his AI leadership role at UTMB. The institution needed a partner who could help them move fast and demonstrate real value, not just run interesting experiments. “We’re not so much interested in, oh, you did something that looks cool on a poster,” Dr. McCaffrey explained. “At this stage, we need true examples where AI is deployed in practice and it brings value to care because that is our mandate.”

For cardiologists at UTMB’s Sealy Heart and Vascular Institute, the workflow is straightforward. They log into Qualified Health’s platform and see a census of patients who have been pre-screened by AI and who have opportunities for more optimized management in areas like heart-failure and valvular disease. The system then brings forward relevant medical and historical context balanced with evidence-based appropriateness criteria to highlight those who might otherwise go unnoticed but who would benefit from improved management. The Claude-powered AI platform surfaces relevant details from each patient’s chart, extracting and synthesizing information that would be impossible to manually compile across a patient population.

“I could spend hours looking through charts and find things to worry about,” Norden said. “But you can’t do that on 10,000 patients.” The system doesn’t replace clinical judgment, he added. It amplifies it, enabling clinicians to apply their expertise at a scope that was previously impossible.

Choosing Claude for clinical accuracy

Qualified Health continuously evaluates multiple large language models through a rigorous internal benchmarking process that combines automated testing with structured review by practicing physicians. Models are assessed on their ability to accurately extract structured clinical information from complex source data, minimize failure modes such as hallucinations, and provide traceable citations back to underlying records.

“Our focus is on precision and reliability,” Norden said. “We need models that can consistently identify the right clinical signals, avoid introducing errors, and make every output fully referenceable to the source data. In our evaluations for this work, Claude demonstrated the strongest performance across those dimensions.”

“Safety is non-negotiable in healthcare,” Norden added. “Anthropic has been a clear leader in building models with strong safety foundations, and that was an important factor in our decision-making.”

The validation process reflects Qualified Health’s roots in algorithmic safety and clinical rigor. Each deployment follows a staged approach that includes retrospective back-testing on historical data, automated evaluations, structured physician review, and controlled rollouts prior to broader use with partners.

“There are no fully automated clinical decisions being made,” Norden emphasized. “Every output is reviewed by clinicians, with direct validation against source data. Human oversight is built into the system by design.”

The outcome

In the first month of deployment, the platform revealed that as many as a third of patients with heart failure have opportunities for improved optimization in guideline directed medical therapy. In the initial wave of review, this translated into dozens of patients with opportunities for evidence-based improvement in medication management which cardiologists could then validate and notify care teams. “This is a great example of AI actively augmenting the clinical workforce”, McCaffrey said. “It’s well known that many patients with heart failure can benefit from improved pharmacologic management but examining this adherence and medication practice across a population just isn’t feasible; we don’t have the clinician bandwidth for that.”

The approach extends beyond cardiology. “We started in cardiology, but this isn’t just a cardiology tool,” McCaffrey noted. “It’s the same problem everywhere—there’s a patient in GI with early cirrhosis, there’s someone in vascular with an aneurysm that’s never been flagged. The information is there. We just haven’t had a scalable way to surface it. The need isn’t for AI to make medical decisions; instead, the need is to bring buried issues to the foreground so that clinicians can make medical decisions.”

Cardiology was a deliberate starting point as a specialty with well-established diagnostic criteria, clear clinical guidelines, and availability of proven interventions with life-saving potential.

Building on UTMB’s success, the initiative is now expanding system-wide. By the end of 2026, new deployments will help health systems across Texas identify patients eligible for evidence-based treatments in primary care, vascular, gastrointestinal, rheumatology, and neurology specialties. Dr. McCaffrey chairs AI work across all UT System health institutions, and the system views itself as responsible for all Texans across its exceptional geographic, medical, and socioeconomic diversity.

Dr. McCaffrey added: “Being able to scale that intelligence, that clinical reasoning, to everyone, everywhere is a really inherent social good.” 

‍Worth accessing:

Qualified Healthhttps://www.qualifiedhealthai.com

Advancing Claude in healthcare and the life sciences

Transform healthcare from insight to action

Read more

Read more

Claude for Healthcare

Claude helps healthcare organizations move faster without sacrificing accuracy, safety, or compliance. Less administrative work, more time with the people you serve.

Read more

Read more

“Safety is non-negotiable in healthcare. Anthropic has been a clear leader in building models with strong safety foundations.”

Justin Norden, MD

Co-Founder, Qualified Health

Posted in Uncategorized | Tagged , , , , | Leave a comment

Hassan Sajwani: “This is an engineer from Elon Musk’s xAI …

Posted in Uncategorized | Leave a comment

The Economist: Who had the most contact with Jeffrey Epstein in the final decade of his life?

Posted in Uncategorized | Leave a comment